XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.22.1

INVESTMENTS | 3 Months Ended
--- | ---
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract] |
INVESTMENTS | INVESTMENTS. The carrying values of our investments that are not part of the consolidated T. Rowe Price investment products are as follows:
(in millions) | 3/31/2022 |  | 12/31/2021
Investments held at fair value |  |  |
T. Rowe Price investment products |  |  |
Discretionary investments | $ | 502.2 |  |  | $ | 518.7 |
Seed capital | 224.6 |  |  | 264.8 |
Supplemental savings plan liability economic hedges | 820.0 |  |  | 881.5 |
Investment partnerships and other investments | 105.0 |  |  | 108.9 |
Investments in affiliated collateralized loan obligations | 9.3 |  | 10.8
Equity method investments |  |  |
T. Rowe Price investment products - seed capital | 134.0 |  |  | 141.7 |
Investments in affiliated private investment funds - carried interest | 642.1 |  | 609.8
Investments in affiliated private investment funds - seed/co-investment | 153.1 |  | 151.3
23% Investment in UTI Asset Management Company Limited (India) | 170.3 |  |  | 165.4 |
Other investment partnerships and investments | 2.5 |  |  | 2.5 |
Held to maturity |  |  |
Investments in affiliated collateralized loan obligations | 115.2 |  | 119.1
U.S. Treasury note | 1.0 |  |  | 1.0 |
Total | $ | 2,879.3 |  |  | $ | 2,975.5 |
The investment partnerships are carried at fair value using net asset value (“NAV”) per share as a practical expedient. Our interests in these partnerships are generally not redeemable and are subject to significant transferability restrictions. The underlying investments of these partnerships have contractual terms through 2029, though we may receive distributions of liquidating assets over a longer term. The investment strategies of these partnerships include growth equity, buyout, venture capital, and real estate. During the three months ended March 31, 2022, net losses on investments included $99.9 million of net unrealized losses related to investments held at fair value that were still held at March 31, 2022. For the same period of 2021, net gains on investments included $38.8 million of net unrealized gains related to investments held at fair value that were still held at March 31, 2021. During the three months ended March 31, 2022 and 2021, certain T. Rowe Price investment products in which we provided initial seed capital at the time of formation were deconsolidated, as we no longer had a controlling interest. Depending on our ownership interest, we are now reporting our residual interests in these T. Rowe Price investment products as either an equity method investment or an investment held at fair value. Additionally, during the three months ended March 31, 2022 and March 31, 2021, certain T. Rowe Price investment products were consolidated, as we regained a controlling interest. The net impact of these changes on our unaudited condensed consolidated balance sheets and statements of income as of the dates the portfolios were deconsolidated or reconsolidated is detailed below.
| Three months ended |  |
(in millions) | 3/31/2022 |  | 3/31/2021 |  |  |  |
Net increase (decrease) in assets of consolidated T. Rowe Price investment products | $ | (97.5) |  |  | $ | (928.1) |  |  |  |  |
Net increase (decrease) in liabilities of consolidated T. Rowe Price investment products | $ | (8.6) |  |  | $ | (15.3) |  |  |  |  |
Net increase (decrease) in redeemable non-controlling interests | $ | (63.0) |  |  | $ | (739.9) |  |  |  |  |
Gains recognized upon deconsolidation | $ | 1.6 |  |  | $ | 2.6 |  |  |  |  |
The gains recognized upon deconsolidation were the result of reclassifying currency translation adjustments accumulated on certain T. Rowe Price investment products with non-USD functional currencies from accumulated other comprehensive income to non-operating income. INVESTMENTS IN AFFILIATED COLLATERALIZED LOAN OBLIGATIONS. There is debt associated with our long-term investments in affiliated collateralized loan obligations (“CLOs”). As of March 31, 2022 and December 31, 2021, the debt is valued at $108.7 million and $113.5 million, and is reported in accounts payable and accrued expenses in our unaudited condensed consolidated balance sheets. The debt includes outstanding repurchase agreements of €66.7 million (equivalent to $73.8 million at March 31, 2022 and $75.9 million at December 31, 2021 at the respective EUR spot rates) and collateralized by the CLO investments. The debt also includes outstanding note facilities of €32.4 million (equivalent to $34.9 million at March 31, 2022 and $36.9 million at December 31, 2021 at the respective EUR spot rates) and are collateralized by first priority security interests in the assets of the consolidated OHA entity that is party to the notes. The debt bears interest at rates based on EURIBOR plus the initial margin, which equals all-in rates ranging from 1.70% to 1.95% as of March 31, 2022. The debt matures on various dates through 2032 or if the investments are paid back in full or cancelled. VARIABLE INTEREST ENTITIES. Our investments at March 31, 2022 and December 31, 2021 include interests in variable interest entities that we do not consolidate as we are not deemed the primary beneficiary. Our maximum risk of loss related to our involvement with these entities is as follows:
(in millions) | 3/31/2022 |  | 12/31/2021
Investment carrying values | $ | 951.9 |  |  | $ | 943.3 |
Unfunded capital commitments | 110.4 |  |  | 94.2 |
Accounts receivable | 94.2 |  |  | 145.1 |
| $ | 1,156.5 |  |  | $ | 1,182.6 |
The unfunded capital commitments totaling $110.4 million at March 31, 2022 and $94.2 million at December 31, 2021 relate primarily to the affiliated private investment funds and the investment partnerships in which we have an existing investment. In addition to such amounts, a percentage of prior distributions may be called under certain circumstances. INVESTMENTS IN AFFILIATED PARTNERS. During 2021, as part of the OHA acquisition, we acquired a majority of the equity interests in entities that have interests in general partners of affiliated private investment funds and are entitled to a disproportionate allocation of income. These entities are considered variable interest entities and are consolidated as T. Rowe Price was determined to be the primary beneficiary. The total assets, liabilities and non-controlling interests of these consolidated variable interest entities are as follows:
(in millions) |  | 3/31/2022 |  | 12/31/2021
Assets |  | $ | 695.4 |  |  | $ | 692.7 |
Liabilities |  | $ | 1.1 |  |  | $ | 56.4 |
Non-controlling interest |  | $ | 272.2 |  |  | $ | 248.7 |

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -URI http://asc.fasb.org/topic&trid=75115024 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 325 -URI http://asc.fasb.org/topic&trid=2197064 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -URI http://asc.fasb.org/topic&trid=2196965 + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration